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SUPPLEMENTARY NOTES
ABSTRACT
Overexpression of Bcl-2 has been observed in 70% of breast carcinomas and the expression levels of Bcl-2 proteins correlate with resistance to a wide spectrum of chemotherapeutic drugs and radiation therapy. In this IDEA grant, we propose an effective structure-based approach to discover small molecule inhibitors of Bcl-2 through structure-based 3D-database search over large chemical databases containing >500,000 structurally diverse, non-peptide, drug-like synthetic compounds or natural products. Using this powerful approach, we have discovered 10 classes of structurally diverse, non-peptidic, drug-like, small-molecule inhibitors of Bcl-2. Our studies also showed that the most promising small-molecule inhibitors of Bcl-2 we have discovered potently bind to Bcl-2 protein, inhibit cell growth and induce apoptosis in breast cancer cells with high levels of Bcl-2 proteins and display good selectivity in cancer cells with low levels of Bcl-2 proteins. Furthermore, our most potent small-molecule inhibitor of Bcl-2 inhibits tumor growth in animal models of human breast cancer. Our results have demonstrated that potent small-molecule inhibitors of Bcl-2 may have a great therapeutic potential for the treatment of human breast cancer by overcoming apoptosis resistance of breast cancer cells.
SUBJECT TERMS
No subject terms provided. In this IDEA grant, we propose an effective structure-based approach to discover small molecules that bind to the Bcl-2 binding pocket. Specifically, we propose to perform structurebased 3D-database search over large chemical databases containing >500,000 structurally diverse, non-peptide, drug-like synthetic compounds or natural products to identify small molecule candidates that can effectively interact with the Bcl-2 binding pocket. Most promising candidate molecules are then tested in appropriate binding and cellular assays to confirm their activity, specificity and mechanism. For the best Bcl-2 inhibitors identified from this project, they will be further evaluated for their anti-cancer activity in vivo and their therapeutic potential for the treatment of human breast cancer with high levels of Bcl-2 protein.
Discovery of novel, non-peptidic, cell permeable Bcl-2 small molecule inhibitors represents the first but very exciting step toward the development of a novel cancer therapy targeted at Bcl-2. The success of this project will pave the way for the development of a small molecule drug through modulation of the Bcl-2 function for the treatment of breast and many other forms of cancers with Bcl-2 overexpression, either alone or in combination with conventional chemotherapeutic drugs or radiation therapy. This task has been essentially completed and was reported last year. As can be seen, although TXT (7.5 mg/kg, i.v. weekly for three weeks) has a good antitumor activity, the combination with either 7.5 mg/kg or 30 mg/kg of (-)-gossypol achieved a much greater anti-tumor activity than either agent alone. Overall, greater than 95% of tumor growth inhibition was achieved when (-)-gossypol was combined with TXT. The results are also highly statistically significant (p < 0.001).
Taken together, our data showed that (-)-gossypol achieves a good anti-tumor activity in vivo in inhibition of tumor growth when used as a single agent. Importantly (-)-gossypol achieves a much greater anti-tumor activity in vivo when used in combination with TXT. These data indicate that (-)-gossypol may have great therapeutic potential to be developed as a novel class of anti-cancer drug for the treatment of human breast cancer and other types of cancer.
Task 4. Preparing scientific publications (6-36 months).
The following manuscripts have been accepted for publications or in preparation. The DOD grant support is acknowledged in these manuscripts. 
Key Research Accomplishments:
(1). We have discovered and characterized gossypol and its enantiomers as potent small-molecule inhibitors of Bcl-2 and Bcl-xL.
(2). We demonstrated that (-)-gossypol has potent activity in human breast cancer cells and other cancer cells with high levels of Bcl-2 and Bcl-xL proteins and show good selectivity in normal cells with low levels of Bcl-2/Bcl-xL proteins. 
